Jefferies Group Weighs in on Zimmer Biomet Holdings, Inc.’s Q3 2017 Earnings (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Investment analysts at Jefferies Group decreased their Q3 2017 earnings per share estimates for shares of Zimmer Biomet Holdings in a research note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now anticipates that the medical equipment provider will earn $1.76 per share for the quarter, down from their previous estimate of $2.03. Jefferies Group has a “Buy” rating and a $148.00 price target on the stock. Jefferies Group also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.27 EPS, FY2017 earnings at $8.24 EPS, FY2018 earnings at $8.73 EPS, FY2019 earnings at $9.86 EPS and FY2020 earnings at $10.82 EPS.

Other equities research analysts have also issued reports about the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday. Citigroup Inc. lifted their price target on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, June 9th. Wells Fargo & Company reaffirmed a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $137.76.

COPYRIGHT VIOLATION WARNING: “Jefferies Group Weighs in on Zimmer Biomet Holdings, Inc.’s Q3 2017 Earnings (NYSE:ZBH)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2017/08/19/jefferies-group-weighs-in-on-zimmer-biomet-holdings-inc-s-q3-2017-earnings-nysezbh-updated-updated.html.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 121.32 on Monday. The firm has a market cap of $24.48 billion, a PE ratio of 34.55 and a beta of 1.21. The firm’s 50-day moving average price is $127.89 and its 200-day moving average price is $121.20. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The company had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.02 EPS.

The firm also recently declared a quarterly dividend, which was paid on Friday, July 28th. Shareholders of record on Friday, June 23rd were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, June 21st. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.

In other news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Chad F. Phipps sold 6,200 shares of the firm’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $116.76, for a total transaction of $723,912.00. The disclosure for this sale can be found here. 1.07% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Parkside Financial Bank & Trust boosted its position in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC boosted its position in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank boosted its position in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its position in shares of Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 84.13% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit